{"id":"559058-4826","orgnr":"559058-4826","name":"SynAct Pharma AB","name_registered_on":"2016-04-12","legal_form":{"code":"AB","name":"Aktiebolag"},"status":"registered","registered_on":"2016-04-12","business_description":"Föremålet för bolagets verksamhet skall vara att utveckla och kommersialisera läkemedel för behandling av inflammation och andra sjukdomar och därmed förenlig verksamhet samt att äga och förvalta aktier.","industries":[{"code":"72109","name":"Annan naturvetenskaplig och teknisk forskning och utveckling"}],"postal_address":{"street":"Scheelevägen 2","postal_code":"22363","city":"LUND","country":"SE","municipality":{"code":"1281","name":"Lund"},"county":{"code":"12","name":"Skåne län"}},"registered_office":{"municipality":{"code":"1281","name":"Lund"},"county":{"code":"12","name":"Skåne län"}},"activity_status":"active","employee_class":{"code":"2","name":"1-4 anställda"},"turnover_class":{"code":"4","name":"5 000 - 9 999 tkr","year":2025},"public_company":{"code":"23","name":"Publikt, Stockholm Small Cap"},"f_tax":"registered","vat":"registered","employer":"registered","registry_source":{"dataset":"bolagsverket_bulkfil","published_on":"2026-11-16"},"annual_reports":[{"from":"2025-01-01","to":"2025-12-31","framework":"IFRS","documents":{"annual_report":"/v1/documents/d3b95f62-ddeb-41ee-b5b2-86532054e2e8.xhtml","certificate":"/v1/documents/6fc8562c-890e-4739-858b-e1699ac0e5f4.xhtml"},"source":{"dataset":"arsredovisningar","file":"2026/26_8.zip"}},{"from":"2024-01-01","to":"2024-12-31","framework":"IFRS","documents":{"annual_report":"/v1/documents/993ba53b-c32f-45bb-ae72-b19bc4656d8a.xhtml","certificate":"/v1/documents/a4af9620-18a1-4fe3-9633-8ee05af01c4a.xhtml"},"source":{"dataset":"arsredovisningar","file":"2025/25_5.zip"}},{"from":"2023-01-01","to":"2023-12-31","framework":"IFRS","documents":{"annual_report":"/v1/documents/42efd7f7-03e0-45e3-97a4-3fc4588f22e5.xhtml","certificate":"/v1/documents/b708c150-873d-4d6a-97ba-970d51cfbf2f.xhtml"},"source":{"dataset":"arsredovisningar","file":"2024/23_4.zip"}},{"from":"2022-01-01","to":"2022-12-31","framework":"IFRS","documents":{"annual_report":"/v1/documents/7e5a16df-0a83-4d7d-81d2-d179c3762ce2.xhtml","certificate":"/v1/documents/e2c028fa-0f79-4d82-bef5-0f42340f8ef5.xhtml"},"source":{"dataset":"arsredovisningar","file":"2023/23_3.zip"}}],"latest_financials":{"from":"2025-01-01","to":"2025-12-31","scope":"group","currency":"SEK","net_sales":0,"operating_profit":-116540000,"profit_after_financial_items":-118991000,"net_profit":-110826000,"total_assets":220518000,"equity":170291000,"long_term_liabilities":28703000,"current_liabilities":21524000,"cash":53406000,"source":{"annual_report":"2025-12-31","document":"/v1/documents/d3b95f62-ddeb-41ee-b5b2-86532054e2e8.xhtml"},"anchors":{"cash":{"text":"53 406","prefix":"21"},"current_liabilities":{"text":"21 524"},"equity":{"text":"170 291","prefix":"828"},"long_term_liabilities":{"text":"28 703"},"total_assets":{"text":"220 518","prefix":"TILLGÅNGAR"}}}}